Beyond GLP-1s: The next chapter of obesity care

The rapid rise of GLP-1 medications such as semaglutide and tirzepatide has transformed obesity treatment. Still, experts say medications alone are not enough to address one of the nation's most pressing chronic diseases.

Engineered probiotic heads to human trials

A probiotic bioengineered by UBC Okanagan researchers to thrive in the inflamed gut is set to enter human clinical trials in Australia this summer, capping a decade-long effort to turn a beneficial bacterium into a treatment ...

page 2 from 40